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Depression is a highly prevalent disorder which exerts a major economic impact in 37 
all European countries.  The brain-gut-microbiota axis has been described as a new 38 
paradigm for advancing understanding and treatment of the disorder. There is now  39 
over-whelming evidence to support the fact that gut microbes have a major impact 40 
on central neurochemistry and behaviour, especially stress related disorders such as 41 
depression. Recent studies indicate that patients with depression have a gut 42 
dysbiosis. The reason for this dysbiosis is uncertain. Over recent decades, dietary 43 
patterns in Europe and elsewhere have undergone major compositional changes, 44 
with increased intakes of red meat, high fat foods, and refined sugars.  Individuals 45 
who consume a Mediterranean diet have lower rates of depression and a recent study 46 
suggests that a Mediterranean diet may have antidepressant properties.  Assuming 47 
this to be the case, which components of the Mediterranean diet mediate the effects?  48 
Highly levels of polyphenols or polyunsaturated fatty acids are obvious candidates.  49 
We in the MyNewGut consortium recommend that patients with depression or 50 
vulnerability to depression should be encouraged to enhance a plant-based diet with 51 












Depression is not only the common cold of psychiatric disorders but one of the most 62 
prevalent medical conditions.  In Europe the economic impact of depression 63 
accounts for one third of the cost of all psychiatric and neurological disease (1). 64 
While several subtypes of mood disorder have been described the most important in 65 
terms of prevalence are major depression (unipolar)  and bipolar affective disorder, 66 
previously called manic depression. The point prevalence of major depression in 67 
Europe is between 3% - 6% and it is clear that no society is immune to the disorder 68 
(2). Despite major investment in studies exploring the biology of depression, it 69 
remains a syndrome diagnosed by the presence of a cluster of symptoms (3) and not 70 
by objective  laboratory investigations. Most, though not all cases of depression arise 71 
due to negative life events in a setting of psychosocial stress, with genetics and early 72 
life adversity frequently yielding vulnerability to the disorder. The core features of 73 
depression are low mood and/or anhedonia, the inability to feel enjoyment. Anxiety 74 
is often an important feature of major depression, though it can be a distinct 75 
disorder, often presenting as generalized anxiety disorder, panic disorder or 76 
obsessive compulsive disorder. 77 
Current pharmacotherapy in Europe and elsewhere for treating major depression 78 
comprises the manipulation of monoaminerigic systems (catecholaminergic and 79 
serotonergic systems). (4). Clinical efficacy of these drugs is limited by a delayed 80 
onset of action and a considerable proportion of patients (maybe as high as 40%) 81 
who do not respond adequately to treatment (5). Psychological therapies, likewise 82 
have limitations, and are used either on their own or in combination with 83 
medication. Cognitive behaviour therapy (CBT) and mindfulness are the most 84 
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widely used and studied psychological therapies.  For many patients a combination 85 
of antidepressants and CBT/mindulness is considered as the optimal therapy. 86 
Over the past decade there has been a major focus on the role of inflammation in the 87 
pathophysiology of depression and in determining vulnerability to the disorder. It is 88 
established that major depression correlates with definite increases in pro-89 
inflammatory cytokines such as inteleukin-1 (IL-1), IL-8 and TNF-alpha (6). These 90 
cytokines potently activate the hypothalamic-pituitary-adrenal axis (HPA) and may 91 
play a major part in maintaining the HPA over-activation seen in depression(7).  92 
Effective treatment of depression by whatever modality is accompanied by 93 
suppression of pro-inflammatory cytokines and decreased activation of the HPA.  It 94 
is of interest from a nutritional perspective that  a Mediterranean diet which is 95 
viewed as having anti-inflammatory effects is associated with less depression than 96 
standard northern European diets (8). 97 
The FP7 EU project MyNewGut (www.mynewgut.eu) is a five-year initiative (2013-98 
2018) integrated by a highly multidisciplinary team that cooperates to disentangle 99 
the role played by our gut microbiota, via interactions with lifestyle factors (e.g. diet, 100 
eating habits, stress, etc.), in the regulation of pathways leading to the development 101 
of obesity and behavioural disorders.  In this review the views of the Consortium in 102 
relation to diet and mood and how such effects are mediated by the microbiota are 103 
laid out. 104 
New paradigm in mental health 105 
The brain-gut-microbiota axis is the focus of the latest paradigm not just in neuroscience, but 106 
specifically in relation to mental health, and has been put forward as a potential watershed 107 
development (9).  There is now an ever accumulating volume of evidence to support the fact 108 
that gut microbes have a major impact on central neurochemistry and behaviour, especially 109 
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stress related responses(10). In humans functional MRI (11) and electroencephalography(12) 110 
have been used to support animal studies. Through what mechanism(s) do gut microbes exert 111 
such significant central influence and how might targeting the brain-gut-microbiota axis 112 
through dietary intervention yield effective therapies for patients with depression? 113 
In reviewing the published literature on the brain-gut-microbiota axis and mental health the 114 
main limitation at this point is the paucity of well designed, adequately powered clinical 115 
studies.  As has been pointed out elsewhere, a majority of papers so far published are from 116 
the pre-clinical arena (9).  Drawing major clinical conclusions from rodent studies is 117 
problematic. 118 
Brain-gut microbe communication 119 
It is argued that gut microbe to brain communication is a black box of which we have limited 120 
understanding (13). However, this may be considered as an overly pessimistic analysis of the 121 
current state of knowledge.  We  know that the brain-gut-microbiota axis is a bidirectional 122 
communication system which enables gut microbes to communicate with the brain, and the 123 
brain in turn to communicate with the gut (14). While brain-gut communication has been the 124 
subject of research for decades an exploration of gut microbes as an important vehicle within 125 
this context has only recently been proposed. The mechanisms of signal transmission are 126 
complex and involve neural, endocrine, immune, and metabolic pathways.  Preclinical studies 127 
have implicated the vagus nerve, that long meandering nerve, as a fundamental neural  route 128 
of communication between gut microbes in the periphery and centrally-mediated behavioural 129 
effects, as demonstrated  by the elimination of central Lactobacillus rhamnosus (JB1) effects 130 
following a  full truncal vagotomy (15).  Epidemiological studies have demonstrated that 131 
individuals who underwent a full truncal vagotomy for treatment of peptic ulcer disease  have 132 
a diminished  risk of Parkinson’s disease as they age (16). The gut microbiota also regulates 133 
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brain monoamines, such as serotonin, by altering levels of precursors; for example 134 
Bifidobacterium longum 35624 has been shown to increase plasma tryptophan levels and thus 135 
impact central 5-HT (17).  Tryptophan is the amino acid precursor of serotonin and the 136 
human brain has limited storage capacity, therefore requiring a continuous supply from the 137 
periphery.  This supply originates from both a dietary source and from intestinal 138 
bifidobacteria who can synthesise the molecule. 139 
Intriguingly, many gut bacteria can synthesise and release neurotransmitters. Lactobacillus 140 
and Bifidobacterium species produce gamma-aminobutyric acid (GABA): Escheridia, 141 
Bacillus and Saccharomyces spp.  produce noradrenaline: Candida, Streptococcus, 142 
Escheridia and Enterococcus spp. can produce 5-HT: Bacillus can produce dopamine: and 143 
Lactobacillus can produce acetylcholine (18, 19). These gut-originated neurotransmitters can 144 
cross the mucosal layer of the intestine, though it is highly unlikely they directly influence 145 
brain chemistry.  Even if they enter the blood stream, which has not been demonstrated, they 146 
cannot cross the blood brain barrier (BBB).  Their impact on brain function therefore is most 147 
likely to occur by acting locally on the enteric nervous system.  Short chain fatty acids 148 
(SCFAs), which include butyrate, propionate and acetate are metabolic products of gut 149 
microbial activity and are a rich energy source.  They can exert central effects either through 150 
conventional GPCRs (G-protein coupled receptors), though such receptors are sparsely 151 
concentrated in the mammalian brain and the half-life of SCFAs is exceedingly short in the 152 
plasma.  Alternatively, they may behave as epigenetic modulators by inhibiting  histone 153 
deacetylases (HDACs)(20). The immune system provides another gut to brain 154 
communication pathway, signalling by way of cytokine molecules (21).  Such molecules 155 
produced at the level of the gut can travel via the bloodstream to the brain.  However, in 156 
normal physiological circumstances they do not cross the BBB, but there is accumulating 157 
evidence to support the view that they signal across the BBB and influence brain regions such 158 
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as the paraventricular nucleus of hypothalamus and circumventricular organs where the BBB 159 
is deficient. If plasma levels of the cytokines IL-1 and IL-6 are elevated by infection or 160 
otherwise they activate the core stress system, the HPA, bringing about the release of cortisol.  161 
This is viewed as the most potent activating mechanism of the stress system and is of special 162 
relevance in disorders such as the depression that emerges with interferon therapy for 163 
hepatitis or melanoma (22).  164 
Psychopathology and gut dysbiosis 165 
There is increasing evidence that some psychiatric disorders such as depression may be 166 
associated with a gut dysbiosis, a microbial imbalance.  The extent to which such a dysbiosis 167 
is central to the pathophysiology of depression has yet to be been fully elucidated. 168 
Depression 169 
Lyte et al (23) found that oral gavage of the pathogen Campylobacter jejuni, in tiny 170 
subclinical doses, which failed to exert an immune response,  resulted in anxiety-type 171 
behaviour in rodents. They also found that areas of brainstem, such as the nucleus tractus 172 
solitarius and lateral parabrachial nucleus, are involved in the processing that results in the 173 
autonomic, neuroendocrine and behavioural responses induced by the gavage.  174 
A recently published epidemiological analysis supports the link between gut infection and 175 
anxiety.  Bruch analysed the Medical Expenditure Panel Survey (MEPS) to prospectively 176 
determine a relationship between intestinal infection and future onset of an anxiety disorder 177 
(24). The data for all respondents who were 18 years of age or older and who did not have an 178 
anxiety disorder at baseline were included. Within the study population, there were 2577 179 
subjects with an intestinal infection in Round 1 and 4239 with an anxiety disorder 180 
commencing subsequently. In total an intestinal infection in Round 1 was associated with a 181 
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significantly increased odds ratio of a subsequent emergent anxiety disorder.  This major 182 
epidemiological study provides solid evidence for a link between intestinal infection and the 183 
development of anxiety. 184 
O’Mahony and  colleagues studied the gut microbiota in a maternal separation model of 185 
depression in rats (25).   They reported an elevation in corticosterone in such animals, 186 
together with an increase in pro-inflammatory cytokines and a decrease in the diversity of gut 187 
microbes.  In a recent study the fecal microbiota was sequenced in a depression study (26).    188 
Forty-six patients with depression and 30 healthy controls were recruited.  High-throughput 189 
pyrosequencing showed that, according to the Shannon index, increased faecal bacterial 190 
alpha-diversity was present  in those currently depressed but not in a group who had 191 
responded to treatment. This suggests that increased alpha diversity is a state rather than trait 192 
marker for depression. Bacteroidetes, Proteobacteria, and Actinobacteria were increased, 193 
whereas Firmicutes were significantly decreased.   Despite the profound inter-individual 194 
variability, levels of several predominant genera differed between the depressives and 195 
controls. The depressives had increased levels of Enterobacteriaceae and Alistipes but 196 
reduced levels of Faecalibacterium. The authors conclude that further studies are necessary to 197 
elucidate the temporal and causal relationships between gut microbiota and depression and to 198 
evaluate the suitability of the microbiome as a biomarker.   In a study conducted at APC 199 
Microbiome Ireland depressed patients had elevated cortisol output together with decreased 200 
faecal microbial richness and surprisingly when rats were given a humanised microbiota from 201 
depressed patients, as opposed to healthy controls, they developed a depressive phenotype 202 
from both a behavioural and immune perspective(27).   203 
Depression co-morbidity 204 
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Depression is frequently co-morbid with a variety of medical illnesses including 205 
cardiovascular disease, metabolic syndrome and the gastrointestinal disorder irritable bowel 206 
syndrome (IBS), which presents with abdominal pain or discomfort and an alteration of 207 
bowel habit in the absence of gross pathology.    In IBS an increase in pro-inflammatory 208 
cytokines in the plasma has been reported(28) together with altered gut barrier function (29).  209 
The latter is thought to lead to a ‘leaky gut’ and the passage of inflammatory molecules such 210 
as lipopolysaccharide (LPS) from gram negative bacteria into the blood stream(30) with 211 
subsequent activation of the immune system via toll-like receptors.  The maternal separation 212 
model of IBS supports the view of an altered gut microbiota in the condition together with a 213 
pro-inflammatory phenotype. 214 
It is possible that a poor quality diet may bring about the altered microbiota observed in 215 
depression.  Narrowing of dietary diversity with reduced intake of essential nutrients can 216 
reduce availability of substrates for specific microbial growth and this could contribute to the 217 
intestinal dysbiosis of depression. 218 
Diet and the microbiota 219 
Over recent decades, dietary patterns in Europe and elsewhere have undergone major 220 
compositional changes, with increased intakes of red meat, high fat foods, and refined sugars. 221 
This ‘Westernization’ of diets together with sedentary lifestyles results in modifications to the 222 
gut microbiota, which may at least partially contribute to the increasing incidence of chronic 223 
inflammatory disorders, such as cardiovascular disease, obesity, inflammatory bowel disorder  224 
and depression (31). If we are to improve the nutritional value of food and positively impact 225 
mental health, we need to more fully understand the biological interactions between the food 226 
and microbiota. Many human studies have assessed dietary impact on the gut microbiota but 227 
they are limited by the difficulties in controlling potential confounding variables especially 228 
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lifestyle behaviours. Studies are limited by the fact that the microbiota is sequenced from 229 
faecal samples which provides no detail of the microbiota in various gut regions.  With these 230 
limitations in mind we have learned some useful lessons in relation to dietary patterns and 231 
microbiota composition. 232 
Mediterranean diet and depression 233 
There is increasing evidence to support the view that poor quality diet is a risk factor for 234 
major depression.  Epidemiological studies have long demonstrated that those on a 235 
Mediterranean diet suffer from less depression (32). Diets rich in fruit, vegetables, grains and 236 
fish seem protective against depression while a diet of highly proceeded food and those with 237 
a high sugar content predispose to depression(33).  However, the data upon which these 238 
conclusions are based are largely observational.  There is a paucity of properly controlled 239 
studies. 240 
A recent study from Australia used a randomized controlled trial (RCT) design to investigate 241 
the efficacy of a dietary program for the treatment of major depression(34).  A structured 242 
dietary support, focusing on improving diet quality using a modified Mediterranean diet was 243 
compared  to a social support control condition.  Sixty-seven patients were recruited fulfilling 244 
criteria for major depression and scoring 75 or less, out of a possible score of 104, on a 245 
Dietary Screening Tool, a score which indicated a poor baseline diet.  If patients were on 246 
antidepressant medication or undergoing psychotherapy, they were required to be on the 247 
same treatment for at least 2 weeks prior to study entry.  The dietary intervention group 248 
showed a significantly greater improvement in depression scores between baseline and 249 
12 weeks than the social support control group.  Overall, the results of this trial suggest that 250 
improving  diet may be a useful  strategy for treating depression or at least as an adjunctive to 251 
conventional therapies.  Another study by Forsyth and colleagues reaches similar 252 
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conclusions(35).  Furthermore, evidence is accumulating to support the view that the way in 253 
which diet impacts health in general is mediated by the gut microbiota(36, 37). 254 
If we assume that a Mediterranean diet is effective in the prevention and perhaps the 255 
treatment of depression, what components of such a diet mediate these effects? 256 
Polyunsaturated fatty acid and mood 257 
The brain is a lipid-rich organ containing mostly complex polar phospholipids, sphingolipids, 258 
gangliosides and cholesterol (38). These are involved in both the morphology and physiology 259 
of neurones. The glycerophospholipids in the brain contain a high proportion of 260 
polyunsaturated fatty acids (PUFA) derived from the essential fatty acids, linoleic acid and 261 
alpha-linolenic acid. The main PUFAs in the brain are docosahexaenoic acid (DHA) derived 262 
from the omega 3 fatty acid, alpha-linolenic acid, and arachidonic acid and docosatetraenoic 263 
acid,  both derived from the omega 6 fatty acid, linoleic acid(39). 264 
 265 
Omega-3 fatty acid is derived from fish oil and there is considerable epidemiological 266 
evidence to indicate that those with a diet rich in fish have a lower incidence of 267 
cardiovascular disease than those with other diets(40).  In recent times, the focus of attention 268 
has been on the impact of omega-3 fatty acids on depression.   Studies indicate that in  269 
countries where there is a high consumption of fish there are lower rates of depression(41).  270 
However, in many European countries in recent decades the intake of omega-3 PUFAs has 271 
declined with a concomitant increase in omega-6 PUFA intake(42).   Hibbeln was one of the 272 
first to draw demonstrate the importance of omega-3 PUFAs in mental health: in  a cross-273 
national study he found a significant negative correlation between worldwide fish 274 
consumption and prevalence of depression (43).  Subsequent studies have found altered 275 
omega-6/omega-3 ratios in the plasma of depressed patients (44) and altered red blood cell 276 
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phospholipids (45).  In post-mortem brain tissue lower DHA levels have been found in the 277 
orbitofrontal cortex of in depressed patients.  278 
Nemets and colleagues studied 22 depressed patients who failed to respond to antidepressant 279 
therapy(46).   The study had a parallel group, double-blind design in which EPA or placebo 280 
was added to the on-going antidepressant.  A significant effect of omega-3  compared with 281 
placebo was found by week three of treatment.  Peet et al   examined the effects of EPA in 70 282 
patients who had antidepressant resistant depression (47).  Patients were randomised to 283 
receive either placebo or EPA in doses of 1, 2 or 4 grams per day for 12 weeks.  They 284 
continued their antidepressant throughout.  Forty-six of the 52 patients receiving the EPA and 285 
14 of the 18 patients receiving placebo completed the 12 weeks study.  The 1 gram per day 286 
group showed a significantly better outcome than the placebo group.  The authors conclude 287 
that EPA 1 gram per day is an effective strategy for augmenting antidepressants in those who 288 
are treatment resistant.  289 
The results with DHA are inconclusive. Thirty-six subjects with major depression assigned to 290 
receive DHA (2 g/d) for 6 weeks did not show differences in the score of the Montgomery-291 
Asberg Depression Rating Scale compared with the placebo-treated group (48).  A number of 292 
open label studies without appropriate controls report benefits. Given the lack of a placebo 293 
control, these results need to be viewed with caution (49) .  294 
A recent meta-analysis of fifteen trials (916 total participants) using omega-3 PUFAs as 295 
either a mono or adjunctive therapy were analysed. Studies were selected based on 296 
prospective, randomized, double-blinded, placebo-controlled study design, if depressive 297 
episode was the primary complaint with or without comorbid medical conditions and, if 298 
appropriate outcome measures were used to assess depressed mood (50). This meta-analysis 299 
concluded that n-3 PUFA supplements with >60% of EPA (in a dose range of 200 to 2200 300 
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mg/d in excess of DHA) ameliorated the clinical condition. However, doses containing 301 
primarily DHA or <60% EPA were not effective against primary depression.   302 
It is known that EPA has a general immuno-suppressive effect with a capacity to suppress 303 
inflammatory states.  This may be relevant in the context of depression which is known to be 304 
associated with an increase in the acute phase protein C-reactive protein (CRP) and pro-305 
inflammatory cytokines.  A recent  study demonstrated the capacity of polyunsaturated fatty 306 
acids to impact the brain-gut axis by increasing levels of bifidobacteria (51).  At this point it 307 
seems reasonable to recommend fish in the diet of patients with depression but there is 308 
insufficient data to recommend omega-3 PUFAs as either a mono or adjunctive therapy in the 309 
disorder. 310 
Probiotics and depression 311 
Fermented foods have long been associated with a health benefit but only recently has that 312 
benefit been extended to mental health. Numerous claims of therapeutic efficacy have been 313 
made for probiotics but most claims are not substantiated by rigorous placebo controlled 314 
studies.  Psychobiotics are defined as bacteria which when ingested in adequate amounts have 315 
a positive mental health benefit (52).  316 
One therapeutic area where the benefits of probiotics have been established is in the common 317 
gastrointestinal disorder IBS.  Several placebo controlled studies indicate that a bifidobacteria 318 
is highly effective in treating the condition(53).  This is of relevance given the fact that up to 319 
40% of patients with IBS have co-morbid depression and many bifidobacteria have anti-320 
inflammatory activity. 321 
The principal rationale for the use of probiotics in treating major depression rests on their 322 
potential for suppressing the pro-inflammatory component of depression. Can 323 
probiotics/psychobiotics alter this aberrant immunology? It was shown that a bifidobacteria 324 
in IBS switched the balance from a pro- to an anti-inflammatory cytokine response (54).  325 
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They found that in response to bifidobacteria treatment there was an increase  in anti-326 
inflammatory IL-10 and a reduction in pro-inflammatory IL-12 activity.  Similar findings 327 
have been reported with Lactobacillus acidophilus (55). 328 
There are several animal models of depression used for drug development. Using the 329 
maternal separation model, Bifidobacterium longum 35624 was found to normalise behaviour 330 
(17) and reduce corticosterone levels.  This may indicate that the specific bifidobacteria strain 331 
has an antidepressant action. 332 
In a recent study, Benton and colleagues used a placebo controlled design to examine the 333 
impact of probiotics on mood in healthy community based subjects.  One-hundred and thirty-334 
two subjects with a mean  age of 62 years were recruited(56).  Over a three week period they 335 
consumed either milk containing a probiotic or placebo daily.  Mood was assessed at baseline 336 
and after 10 and 20 days of treatment.  Those who rated their mood as poorest at baseline 337 
reported on average an improvement on probiotic by the end of the study.  This improvement 338 
was not noted on placebo. Whether these findings translate to a clinical sample remains to be 339 
seen. 340 
The effects of Lactobacillus rhamnosus HN001 given in pregnancy and postpartum on 341 
symptoms of maternal depression and anxiety in the postpartum period was assessed (57).  342 
Two hundred and twelve women were randomised to HN001 and 211 to placebo.  Women 343 
who received HN001 had significantly lower depression and anxiety scores in the postpartum 344 
period.  The results strongly support the view that the psychobiotic is protective against the 345 
emergence of postpartum symptoms.  This is the best human intervention study so far in the 346 
literature. 347 
Overall, it seems reasonable to conclude that psychobiotic studies in depressed patients are 348 
urgently required. 349 
Prebiotics and depression 350 
15 
 
Prebiotics are fibres metabolised by the microbiota and capable of increasing the levels of 351 
good bacteria such as bifidobacteria.  Prebiotics are found in vegetables such as celery, 352 
Jerusalem artichoke, garlic etc. A number of small clinical controlled trials have assessed the 353 
efficacy of certain prebiotics on psychological outcomes with promising results. Schmidt and 354 
colleagues demonstrated that 3-week supplementation with a galactooligosaccharide (GOS) 355 
prebiotic, which has been shown to stimulate bifidobacterial growth, in healthy volunteers 356 
significantly reduced waking cortisol response, the stress hormone strongly linked to anxiety 357 
and depression (58). Moreover, a B-GOS cohort demonstrated altered behavioural outcomes 358 
through a decrease in attentional vigilance to negative versus positive information in a dot-359 
probe task compared to placebo. It is interesting to note, however, that fructooligosaccharide 360 
(FOS) supplementation had no effect. These results suggest that shaping of microbiota 361 
composition through prebiotic intake could influence behavioural outcomes. In humans, 362 
prebiotic supplementation with trans-GOS not only enhanced bifidobacterial growth and 363 
improved bloating symptoms, but in addition significantly reduced anxiety scores in IBS 364 
sufferers (59). 365 
Polyphenols 366 
Polyphenols are undoubtedly the most numerous among the groups of phytochemicals 367 
present in plants.  They are broadly divided into flavonoids and non-flavonoids.  Resveratrol 368 
which is found in red wine has potent CNS actions.  In an animal model of depression it has 369 
been shown to reduce depressive type behaviours while attenuating the release of both 370 
corticosterone and pro-inflammatory cytokines (60).  It also exerts anti-oxidant activity acting 371 
through sirtuins, is known to be metabolised by the microbiota and influences the 372 
Firmicutes/Bacteroidetes ratio in the intestine (61).  To date there are no published controlled 373 
trials of resveratrol in depressed patients. 374 
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The polyphenol natural product curcumin possesses a variety of biological and 375 
pharmacological properties. Curcumin was found to reduce salivary cortisol levels in 376 
depressed patients relative to that seen in the placebo group(62). Recent data also indicates an 377 
impact in increasing gut microbial diversity (63).  378 
MyNewGut Consortium recommendations 379 
The Mediterranean diet is associated with lower rates of depression, impacts optimally on the 380 
gut microbiota and increasing evidence indicates that such a diet has antidepressant 381 
effects(64). Patients with depression or vulnerability to depression should be encouraged to 382 
enhance a plant-based diet with a high content of grains and fibres.   High fibre diets are 383 
associated with fewer symptoms of depression. When analyzed by the source of fiber, diets 384 
higher in total fiber (more than 27 grams per day), and fiber from vegetables and 385 
breads/cereals (mostly whole grain) were associated with a 42%, 46%, and 41% reduced 386 
likelihood of having depressive symptoms, respectively(65). A decreased consumption of 387 
red, meat especially of processed meat(66), a regular intake of fish(67) and fermented 388 
foods(68) should be recommended.  The intake of sodium and refined sugar should be 389 
restricted. Vigorous aerobic exercise consistent with the age and physical health of the patient 390 
should be encouraged(69). 391 
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Figure Legends 575 
Fig. 1  Shows how stress and poor diet combine to produce a gut dysbiosis and the symptoms 576 
of depression 577 
 578 
Fig. 2 Shows foods with high prebiotic content and capable of stimulating the growth of 579 
‘good’ bacteria 580 
